Nutraceutical ingredient solutions company AIDP's green kiwifruit powder, Actazin, has been granted 14 digestive health claims for use within the Canadian market.
The decision, which was recently approved by the country's regulatory board, Health Canada, is based on clinical research that shows the ingredient's potential in enhancing protein digestion, gut health and gut motility.
Actazin — an ingredient rich in the bioactive proteolytic enzyme actinidin — is a prebiotic that is designed to reduce bloating and support digestive health.
According to AIDP, it is ideal for those with constipation or moderate gastrointestinal pain, as well as those on their weight loss journey.
The company will now be able to use these 14 allocated health claims in marketing campaigns within the region, which include, but are not limited to:
- Helps support bowel function through regularity
- Helps support protein digestion
- Helps support digestive comfort
- Actazin is a source of actinidin
- Actazin is a natural source of digestive enzymes originally derived from the green kiwifruit
- Helps to relieve gastrointestinal discomfort
- A source of antioxidants
“We are delighted to receive this approval from Health Canada as this not only demonstrates the safety of Actazin, but also reinforces the strength of the science surrounding this ingredient,” said AIDP's President, Mark Thurston.
Actazin, manufactured by Anagenix of New Zealand, is exclusively distributed by AIDP Inc. in North America.